Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, and other mature T-cell lymphomas, will be featured in three poster presentations at the American Society of Hematology (ASH) 2025 annual meeting in Orlando, FL. The presentations will include new findings on mogamu ...

Group 1 - Kirin Holdings Co. is a notable stock in the Consumer Staples sector, currently ranked 14 in the Zacks Sector Rank, which evaluates 16 different groups based on the average Zacks Rank of individual stocks [2] - The Zacks Rank model, which focuses on earnings estimates and revisions, currently assigns Kirin Holdings Co. a Zacks Rank of 2 (Buy), indicating a positive outlook for the stock [3] - Year-to-date, Kirin Holdings Co. has achieved a return of approximately 13.3%, significantly outperforming the average return of -0.3% for the Consumer Staples sector [4] Group 2 - Kirin Holdings Co. operates within the Beverages - Alcohol industry, which consists of 16 stocks and is currently ranked 199 in the Zacks Industry Rank, with the industry showing a loss of about 0.7% year-to-date [6] - In comparison, another stock in the Consumer Staples sector, Service Corp. (SCI), has a year-to-date return of 1.2% and is ranked 2 (Buy) as well [5] - The Funeral Services industry, where Service Corp. operates, has three stocks and is ranked 29, with a year-to-date performance of -0.2% [6]

Core Insights - Kura Oncology has received a $30 million milestone payment from Kyowa Kirin for the dosing of the first patient in the second Phase 3 trial of ziftomenib, bringing total milestone payments received to $105 million, with expectations of up to $315 million in additional near-term milestones [1][2]. Group 1: Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting cancer signaling pathways and addressing hematologic malignancies and solid tumors [3]. - The company is developing ziftomenib, a menin inhibitor aimed at specific genetic drivers of acute myeloid leukemia (AML), and is pioneering advancements in menin inhibition for both acute leukemias and solid tumors [3]. Group 2: Clinical Trials - The KOMET-017 trial consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 trials evaluating ziftomenib in combination with intensive and non-intensive chemotherapy regimens for patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML [2]. - Kura believes that KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings [2].

Core Points - Kyowa Kirin International has appointed Julie Dehaene-Puype as President for the Region, effective November 1, 2025 [1] - Julie Dehaene-Puype succeeds Jeremy Morgan, who has been serving as President for the International Region since 2023 [1] - Jeremy Morgan will transition to an advisory role within the business following his tenure [1]

Core Insights - Boehringer Ingelheim has licensed a pre-clinical program from Kyowa Kirin to develop a potential first-in-class small molecule for autoimmune diseases [1][3] - Autoimmune diseases affect approximately one in ten people globally, highlighting a significant unmet medical need for effective treatments [2][6] - The agreement allows Boehringer Ingelheim exclusive worldwide rights to develop the small molecule, with Kyowa Kirin eligible to receive up to €640 million in various payments and royalties [3] Company Overview - Boehringer Ingelheim is a biopharmaceutical company focused on human and animal health, emphasizing innovative therapies for high unmet medical needs [4] - Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company with over 70 years of experience in drug discovery and biotechnology innovation [5]

Core Insights - Kura Oncology has received a $30 million milestone payment following the dosing of the first patient in the KOMET-017 Phase 3 clinical trials for ziftomenib, an investigational oral menin inhibitor [1] - The KOMET-017 trials are designed to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens for patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia [2] - Kura Oncology is focused on precision medicines for cancer treatment, with a pipeline targeting cancer signaling pathways and addressing hematologic malignancies and solid tumors [3] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer treatment [3] - The company is advancing ziftomenib, a menin inhibitor aimed at specific genetic drivers of acute myeloid leukemias, and is also exploring farnesyl transferase inhibition for solid tumors [3]

Company Overview - Kirin Holdings Co. is part of the Consumer Staples sector, which includes 184 companies and is currently ranked 16 in the Zacks Sector Rank [2] - The company has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3] Performance Analysis - Kirin Holdings Co. has achieved a year-to-date return of approximately 12.3%, significantly outperforming the average gain of 1.2% in the Consumer Staples sector [4] - In comparison, the Beverages - Alcohol industry, which includes Kirin Holdings, has seen an average loss of 3.3% this year, further highlighting the company's strong performance [6] Industry Context - The Consumer Staples sector is currently ranked 16 among 16 groups, while the Beverages - Alcohol industry ranks 210 among 210 industries [2][6] - Another notable performer in the Consumer Staples sector is US Foods, which has a year-to-date increase of 13.1% and also holds a Zacks Rank of 2 (Buy) [5] Future Outlook - Investors are encouraged to monitor Kirin Holdings Co. and US Foods for potential continued strong performance in the Consumer Staples sector [7]

Core Insights - Ziftomenib is being evaluated in combination with approved FLT3 inhibitors for frontline treatment of acute myeloid leukemia (AML) [1][2] - FLT3 mutations are prevalent in approximately 30% of newly diagnosed adult AML patients and up to 50% in those with NPM1-mutated AML, highlighting the significance of FLT3 as a target [1] - The KOMET-007 clinical trial has commenced, focusing on ziftomenib's efficacy alongside cytarabine, daunorubicin, and quizartinib for newly diagnosed AML patients [1][2] Company Overview: Kura Oncology - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting hematologic malignancies and solid tumors [4] - Ziftomenib, a menin inhibitor, is under development to address specific genetic drivers of acute myeloid leukemias [4] Company Overview: Kyowa Kirin - Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company with over 70 years of experience in drug discovery and biotechnology innovation [5] - The company is committed to developing novel medicines and treatments for high unmet medical needs, including hematological diseases and rare diseases [5]

Core Insights - The first patient has been dosed in the KOMET-017 clinical trial, which evaluates ziftomenib, a menin inhibitor, for treating newly diagnosed acute myeloid leukemia (AML) patients with specific genetic mutations [1][2] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting hematologic malignancies and solid tumors [3] - Kyowa Kirin is a Japan-based global specialty pharmaceutical company dedicated to drug discovery and biotechnology innovation, particularly in hematological diseases and rare diseases [5] Clinical Trial Details - The KOMET-017 trial consists of two Phase 3 studies: one assessing ziftomenib with intensive chemotherapy (cytarabine/daunorubicin) and the other with non-intensive chemotherapy (venetoclax/azacitidine) [2][3] - The intensive trial will evaluate minimal residual disease (MRD) negative complete response (CR) and event-free survival (EFS) as dual-primary endpoints, while the non-intensive trial will assess CR and overall survival (OS) [2][3] Market Potential - The trials aim to confirm the efficacy of ziftomenib in nearly half of newly diagnosed AML patients, addressing a significant unmet medical need for safe and effective treatment options [2][3] - The FDA's acceptance of MRD negative CR and CR as primary endpoints for accelerated approval is seen as a groundbreaking opportunity to expedite ziftomenib's availability to patients [2]

Company Overview - Kyowa Kirin, Inc. is a wholly owned subsidiary of Kyowa Kirin Co. Ltd, focused on developing solutions for rare diseases, particularly in oncology [1][5] - The company has over 70 years of experience in drug discovery and biotechnology innovation, aiming to deliver novel medicines and treatments with life-changing value [7] Industry Context - Cutaneous T-cell lymphoma (CTCL) is a rare form of blood cancer that primarily affects the skin, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common subtypes [2][6] - Diagnosis of CTCL can be challenging, often taking patients 2-7 years to receive an accurate diagnosis, which can lead to worse prognoses [2][5] Product Launch - Kyowa Kirin has launched a new staging tool for healthcare providers to assist in the accurate staging of patients with MF and SS, available on PROBEinCTCL.com [1][5] - The tool simplifies the staging process by using up to 20 Yes/No questions and real clinical case imagery, guiding users through the TNMB system [3][4] Clinical Relevance - The staging tool is designed to enhance clinical judgment by translating complex guidelines into a practical assessment, thereby supporting more consistent and informed care [2][3] - The tool is based on established guidelines from the National Comprehensive Cancer Network and recommendations from various oncology organizations [4]